Option chain shows key data for Personalis's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Personalis.

Personalis (NASDAQ:PSNL) Stock, Option Chain

Personalis

Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.

Usa,America,Trade,War,Economy,Conflict,Tax,Business,Finance, - 

News

Initiation

Markets

Analyst Ratings

AXGN

BFLY

BPMC

EZPW

PSNL

This Blueprint Medicines Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

Cathie Wood's Buys The Dip In Tempus AI, Coinbase But Sells Ark's Bitcoin ETF Shares Amid Crypto Meltdown

Equities

Tech

ETFs

ABSI

ARKF

ARKK

ARKQ

ARKW

IBTA

PATH

RBLX

ROKU

RXRX

Ark Invest made significant trades on Friday, selling shares of RBLX, ROKU, PATH and buying shares of IBTA, PSNL, ABSI, and RXRX.

Cathie Wood-Led Ark Invest Offloads Roblox, Roku, UiPath As Markets Take A Dip

Set,Of,Racing,Tires,Goodyear,Label,Motor,Sport,Car,Equipment.

Intraday Update

Movers

Trading Ideas

ABNB

BEAM

DKNG

PACB

PONY

UDMY

Goodyear Tire &amp; Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday

Personalis Inc

Press Releases

Personalis Reports Preliminary Fourth Quarter and Full Year 2024 Revenue

New Nature Medicine Publication Shows ctDNA Levels Linked to Recurrence Risk in Lung Cancer

Personalis to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Personalis to Announce Fourth Quarter and Full Year 2024 Financial Results

Personalis to Participate at the TD Cowen's 45th Annual Health Care Conference

Personalis Reports Fourth Quarter and Full Year 2024 Financial Results

New Publication from ICR and Royal Marsden Researchers Highlights the Importance of Ultra-Sensitive ctDNA Testing for Early-Stage Breast Cancer Recurrence Detection

Personalis to Participate at the 24th Annual Needham Virtual Healthcare Conference

Personalis and Academic Partners to Present Latest Data on Ultrasensitive ctDNA Test for Residual Cancer and Recurrence Detection

Personalis to Announce First Quarter 2025 Financial Results

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Akoya Biosciences

Atlantic International Corp. - Common Stock

Atlantic International

BioLife Solutions

Codexis

Champions Oncology

Cytek Biosciences

CryoPort

Fortrea Holdings

Standard BioTools

Lifecore Biomedical

Mesa Laboratories

Maravai LifeSciences Holdings, Inc. - Class A common stock

Maravai LifeSciences

MaxCyte

Niagen Bioscience

Nautilus Biotechnology, Inc. - Common Stock

Nautilus Biotechnology

OmniAb

Pacific Biosciences of California, Inc. - Common Stock

Pacific Biosciences

Quantum-Si Incorporated - Class A Common Stock

Quantum-Si

Quanterix

Rapid Micro Biosystems, Inc. - Class A Common Stock

Rapid Micro Biosystems

Seer

Alpha Teknova

10x Genomics

Needham

Craig-Hallum

HC Wainwright & Co.

Lake Street

BTIG

Comments

Personalis

Personalis (PSNL) Options

No option chain data available. Please try again later

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell